AL

Align Technology, Inc.

ALGNHealthcareNASDAQ

Medical Instruments & Supplies

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$4.03B
+0.9% YoY
Net Income
$410.4M
-2.6% YoY
EBITDA
$822.7M
+0.7% YoY
Free Cash Flow
$533.0M

Scan Results

Daily timeframe
6 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 7 MACD Positive CrossoverHistogram +1.2100, positive momentum
Jul 6 MACD Positive CrossoverHistogram +0.6876, positive momentum
About Align Technology, Inc.

Align Technology, Inc. provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally. The company carries a $12.66B market cap, placing it firmly in the large-cap category. The company's Clear Aligner segment offers Invisalign comprehensive package to treat adults and teens malocclusion and features, and orthodontic needs of teenage or younger patients; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients between the ages of six and ten years with a mixture of primary/baby and permanent teeth.

Key stats
Market Cap$12.66B
P/E (TTM)29.96
Fwd P/E14.29
EPS$5.90
Beta1.67
52W Change-7.3%
ROE10.8%
Analysis

The balance sheet looks solid with $1.06B in cash comfortably exceeding the $116.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $533.0M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 10.8% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 7.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $3.73B (2022) to $4.03B (2025).

Align Technology, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing ALGN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms